Device Technology — Patient-focused Dry Powder Inhalers
2
Device Technology MannKind Corporation 1 T he Dreamboat system was designed to be an efficient, simple, and low cost breath-pow- ered inhaler technology platform that is adapt- able to a broad range of products and therapies. High flow resistance coupled with a concept called “flow balance” enables convenient inhaler formats that are easy to use and function consis- tently with low patient inhalation efforts. S elf-administration of pulmonary products is driven by patient compliance, so the inhalers must be user-friendly and perform consis- tently. To this end, MannKind technology uses the patient’s inhalation effort to deliver the dose in a single inhalation. This system efficiently and aggressively focuses the energy supplied by the patient directly onto the dry powder resulting in high delivery performance. W hen utilized with MannKind’s Technosphere ® formulations, greater than 90% of the powder is delivered to the patient with ~70% of that delivered in the respirable range. The Dreamboat Inhalation System shows M annKind’s approach to pulmonary delivery of APIs with a dry powder inhalation for- mula is based on adherence to several key principles: Simplicity through breath-powered delivery Consistency using high flow resistance Adaptability for a variety of powders and user groups Modularity of a platform-based delivery technology Portability with a discreet, small system Scale-ability in high- and low-volume applications Sensitivity to environmental exposure T hrough extensive clinical experience and market research MannKind has developed a new line of cost effective, innovative breath- powered devices. Our first embodiment, called Dreamboat™, is a reusable patient-friendly inhaler utilizing unit dose cartridges. Dreamboat Overview Dreamboat Technology Dreamboat Development Patient-focused Dry Powder Inhalers Powder Intersection Mouthpiece Inlet Cartridge Inlet To Patient Flow Path Dreamboat Inhaler Flow Path
Transcript of Device Technology — Patient-focused Dry Powder Inhalers
Device Technology
MannKind Corporation
1
The Dreamboat system was designed to be an efficient, simple, and low cost breath-pow-
ered inhaler technology platform that is adapt-able to a broad range of products and therapies. High flow resistance coupled with a concept called “flow balance” enables convenient inhaler formats that are easy to use and function consis-tently with low patient inhalation efforts.
Self-administration of pulmonary products is driven by patient compliance, so the inhalers
must be user-friendly and perform consis-tently. To this end, MannKind technology uses the patient’s inhalation effort to deliver the dose in a single inhalation. This system efficiently and aggressively focuses the energy
supplied by the patient directly onto the dry powder resulting in high delivery performance.
When utilized with MannKind’s Technosphere® formulations, greater than
90% of the powder is delivered to the patient with ~70% of that delivered in the respirable range. The Dreamboat Inhalation System shows
MannKind’s approach to pulmonary delivery of APIs with a dry powder inhalation for-
mula is based on adherence to several key principles:
Simplicity through breath-powered delivery
Consistency using high flow resistance
Adaptability for a variety of powders and user groups
Modularity of a platform-based delivery technology
Portability with a discreet, small system
Scale-ability in high- and low-volume applications
Sensitivity to environmental exposure
Through extensive clinical experience and market research MannKind has developed
a new line of cost effective, innovative breath-powered devices. Our first embodiment, called Dreamboat™, is a reusable patient-friendly inhaler utilizing unit dose cartridges.
Dreamboat Overview
Dreamboat Technology
Dreamboat Development
Patient-focused Dry Powder Inhalers
Powder IntersectionMouthpiece Inlet
Cartridge Inlet
To Patient
Flow Path
Dreamboat Inhaler Flow Path
Device Technology
MannKind Corporation
2
For more information about MannKind Corporation and its technology, visit: http://www.mannkindcorp.com
very little change in performance over a wide range of relevant pressure drops (flow rates) and produces high bioavailability. In addition, a handling study has shown the device is compat-ible with pediatric use.
The manufacture of the Dreamboat Inhalation System is cost effective, featuring a 5-part
inhaler and a 2-part cartridge that are:
Highly amenable to automatic (top down) assembly
Scaled to 16 cavity and 96 cavity component molding
Manufactured from standard compliant resins: PBT, ABS, PP, and HDPE resins
The Dreamboat inhalation system is being expanded to a variety of other inhaler em-
bodiments featuring the same user appeal and performance. Adjustments to meet the needs of specific API formulations and specific clinical indications can be easily implemented.
In addition, the Dreamboat principles have been used to develop the “Cricket” device family.
This novel pulmonary delivery device is designed for acute, time of need, and short duration treat-ments. It offers significant advantage in a single use, 2-part low cost format.
Dreamboat Development (continued)
MannKind’s Vision
Dreamboat Delivery Performance
Cumulative Geometric Particle Size Distributionsat Various Inhalation Pressures
0102030405060708090
100
0 2 4 6 8 10 12 14 16 18 20Geometric Diameter (µm)
Cum
ulat
ive
Dis
trib
utio
n (%
)
2 kPa
4 kPa
6 kPa
8 kPa
Dreamboat Inhaler and Cartridge Assembly
MouthpieceCover
Mouthpiece
Top
Rack
Bottom
Lid
Cup
Multi-use Dreamboat Family
Disposable Cricket Family
Patient-focused Dry Powder Inhalers
